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Increasing numbers of Neisseria gonorrhoeae strains with decreased susceptibilities to ceftriaxone and other
oral cephalosporins widely used for the treatment of gonorrhea have been isolated in Sydney, Australia, over
several years. In this study, we examined the complete penicillin-binding protein 2 (PBP 2) amino acid
sequences of 109 gonococci, selected on the basis of their diverse temporal and geographic origins and because
they exhibited a range of ceftriaxone MICs: <0.03 g/ml (n  59), 0.06 g/ml (n  43), and 0.125 g/ml (n 
7). Auxotyping, serotyping, and genotyping by N. gonorrhoeae multiantigen sequence typing sequence-based
analysis was also performed. In total, 20 different amino acid sequence patterns were identified, indicating
considerable variation in the PBP 2 sequences in this study sample. Only some of the N. gonorrhoeae isolates
with significantly higher ceftriaxone MICs contained a mosaic PBP 2 pattern, while more isolates exhibited a
nonmosaic PBP 2 pattern containing an A501V substitution. Although particular N. gonorrhoeae genotypes in
our sample were shown to be less susceptible to ceftriaxone, the reduced susceptibility to ceftriaxone was not
specific to any particular genotype and was observed in a broad range of auxotypes, serotypes, and genotypes.
Overall, the results of our study show that N. gonorrhoeae strains exhibiting reduced sensitivity to ceftriaxone
are not of a particular subtype and that a number of different mutations in PBP 2 may contribute to this
phenomenon.
The options for the effective treatment of Neisseria gonor-
rhoeae infections have been significantly reduced over time by
the emergence and spread of gonococci resistant to the peni-
cillins, tetracyclines, and the macrolide and quinolone groups
of antibiotics (22). Cephalosporin antibiotics are now the
mainstay of treatment in many settings, and the injectable
agent ceftriaxone is used extensively in Australia and else-
where. However, over recent years, reports, most notably from
Japan (1, 8, 21), but also elsewhere (7, 27), of N. gonorrhoeae
strains with decreased susceptibility to cephalosporin agents
have appeared with increasing frequency.
The mechanism of gonococcal resistance to ceftriaxone is
still unclear. N. gonorrhoeae has two penicillin-binding proteins
(PBPs 1 and 2) that are the major targets of beta-lactam an-
tibiotics. PBP 2, which is encoded by the penA gene, has a
10-fold greater affinity for penicillin than PBP 1 (6). Thus,
mutations in PBP 2 are the major contributor to the emergence
of chromosomally mediated resistance to beta-lactam antibi-
otics in N. gonorrhoeae, and particular attention has been paid
to the penA gene. Alterations in penA that affect the activities
of beta-lactam antibiotics have long been recognized. Insertion
of a single aspartic acid residue preceding Asp-345 (Asp-345A)
in PBP 2 resulted in the expression of an altered PBP 2 and
decreased susceptibility to penicillins (3). The acquisition by
gonococci of other mutations and sequential alterations to
other genes was shown to result in cumulative high-level chro-
mosomal resistance to the penicillins (18), but these changes
were said to have but little effect on the clinical efficacies of
cephalosporin antibiotics (8).
Ameyama et al. (1) described a mosaic penA gene that was
associated with reduced susceptibility to a number of beta-
lactam agents, including cephalosporins, in gonococci from
Tokyo, Japan. The mosaic penA gene was thought to be ac-
quired by gonococci from commensal Neisseria strains by in
vivo transformation (19). Reductions in the susceptibilities of
in vitro transformants with this mosaic sequence were much
greater for oral cephalosporins than for ceftriaxone. Ito et al.
(8) examined the penA sequences of 70 clinical isolates of N.
gonorrhoeae from Gifu, Japan, with a range of susceptibilities
to ceftriaxone and other beta-lactam agents and described 10
PBP 2 patterns of sequence alteration numbered patterns I to
X. The distribution of MICs for penicillin, the oral agents
cefixime and cefdinir, and the injectable agent ceftriaxone was
correlated with the penA patterns determined. Isolates with
patterns I to IX contained the Asp-345A insertion, but isolates
with pattern X did not; rather, they possessed the mosaic PBP
2 sequence described by Ameyama et al. (1). The MICs of
ceftriaxone for gonococci with pattern X that contained the
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mosaic penA gene ranged from 0.015 to 0.25 g/ml but were
said to be “significantly higher” than the MICs of isolates with
patterns I to IX.
Tanaka et al. (21) examined the alterations present in a
multiresistant gonococcus isolated in Fukuoka City, Japan,
that was also less susceptible to ceftriaxone (MIC, 0.5 g/ml).
That group found mutations present in penA, mtrR, penB, and
ponA and postulated that mutations that confer high-level re-
sistance to penicillin also confer resistance to cephalosporins,
including ceftriaxone. Although their isolate possessed the mo-
saic gene described by Ameyama et al. (1) and Ito et al. (8), it
also lacked the Asp-345A substitution in PBP 2. Lindberg et al.
(12) also noted that polymorphisms were present in penA,
mtrR, penB, and ponA in 18 gonococci less susceptible to ceftri-
axone and concluded that an “unambiguous” association ex-
isted between the increased ceftriaxone MICs, these polymor-
phisms, and penA mosaic alleles. Takahata et al. (20) more
recently demonstrated that particular additional amino acid
substitutions in the mosaic PBP 2 sequence were associated
with decreased susceptibility to cefixime but had little effect on
susceptibility to ceftriaxone. That study also found only minor
reductions in ceftriaxone susceptibility in transformation ex-
periments that introduced the full-length mosaic into a suscep-
tible strain. We (26) described a second mosaic PBP 2 se-
quence with an Asp-345A change, but without the three key
substitutions described by Takahata et al. (20), in a gonococcus
fully susceptible to ceftriaxone and suggested that the extent of
the contribution of mosaic PBP 2 sequences to reduced ceftri-
axone susceptibility was yet to be fully elucidated.
In this study, selected gonococci that were isolated between
1997 and 2005 in Sydney, Australia, and that had altered sus-
ceptibilities to ceftriaxone were examined together with iso-
lates susceptible to ceftriaxone. We explored further the rela-
tionship between penA alteration and ceftriaxone susceptibility
by sequencing the penA genes of all isolates. Ito et al. (8) and
a Danish group (7) have also suggested that the spread of these
gonococci with decreased susceptibilities to ceftriaxone may be
the result of the wider dissemination of a limited number of
gonococcal subtypes. We therefore typed and compared all
isolates by phenotypic and genotypic procedures and included
in the selection of the strains studied a number of gonococci
that were examined in Australia but that were isolated from
patients who acquired their infection in a number of different
countries.
MATERIALS AND METHODS
N. gonorrhoeae strains. The South Eastern Area Laboratory Services labora-
tory in Sydney is the reference laboratory for N. gonorrhoeae for the state of New
South Wales, Australia. It undertakes the primary isolation of N. gonorrhoeae
from clinical samples from a number of sexual health clinics and hospitals and
also receives isolates from public- and private-sector laboratories throughout the
state. Approximately 1,200 gonococcal isolates are examined and stored annu-
ally, as described previously (11). A total of 109 gonococcal clinical isolates were
retrospectively selected on the basis of their ceftriaxone MICs and their geo-
graphical and temporal diversities. The ceftriaxone MICs for the isolates were in
the range of0.008 to 0.03 g/ml (n 59), 0.06 g/ml (n 43), and 0.125 g/ml
(n  7). The penicillin G MICs were in the range of 0.125 g/ml (n  6),
0.125 g/ml to 0.5 g/ml (n  18), and 1.0 g/ml (n  75); and another 10
isolates were penicillinase-producing gonococci (see Table 3). The isolates ex-
amined included local and international strains; 13 isolates were obtained from
various parts of Asia (China, n  1; Indonesia, n  1; Japan, n  3; Korea, n 
5 [28]; Mongolia, n  1 [13]; not specified, n  2), and the remaining 96 strains
were collected from various regions of the Australian state of New South Wales.
The years of isolation included 1988 (n  3), 1997 (n  1), 1999 (n  1), 2000
(n 3), 2001 (n 12), 2002 (n 11), 2003 (n 7), 2004 (n 12), and 2005 (n
59). Included among the isolates examined were gonococci used as reference
cultures in World Health Organization and Australian quality assurance pro-
grams (2, 24, 27) and gonococci less susceptible to ceftriaxone, which were kindly
supplied by T. Muratani (16).
Nucleotide sequencing of penA genes. The full-length penA gene sequences of
the isolates were amplified and sequenced as described previously (8). Briefly,
three separate PCRs were used to amplify three fragments of the penA gene. The
PCR products were purified and then sequenced by using an ABI PRISM
BigDye sequencing kit (Applied Biosystems).
Phenotypic and genotypic characterization and MIC determinations. Pheno-
typic and genotypic characterization and MIC determinations were performed
for all 109 isolates as described previously (11, 24). Briefly, the extended phe-
notype of each isolate was derived by determination of the antibiotic suscepti-
bility by the agar plate dilution methods of the Australian Gonococcal Surveil-
lance Programme (24), which uses Sensitest agar (Oxoid, Basingstoke, United
Kingdom) with 8% saponin-lysed horse blood as the test medium and an inoc-
ulum of 104 CFU per spot, and by auxotype/serovar classification. The ceftriax-
one MIC was determined in triplicate examinations on separate occasions for
those gonococci for which the MIC was raised. Auxotyping was done by the
method of La Scolea and Young (10), and serovar determinations were done
with a panel of 14 monoclonal reagents (Boule, Huddinge, Sweden) and by use
of the nomenclature of Bygdeman (4) Genotyping was performed by N. gonor-
rhoeae multiantigen sequence typing (NG MAST), as described previously (15).
Statistical analysis. Data analysis was performed by using the Mann-Whitney
U test. Significance was set at a P value of 0.05.
RESULTS
Mutations of PBP 2 in clinical isolates. The complete nu-
cleotide sequences of the penA genes of 109 clinical isolates of
N. gonorrhoeae were determined. In total, 20 different amino
acid sequence patterns were identified (patterns I to XXIII;
Fig. 1), indicating the presence of considerable variation
among the PBP 2 proteins in this study sample. Briefly, the first
340 amino acids of all 20 patterns except pattern X were
identical to those in the GenBank reference sequence (acces-
sion number M32091). Various substitutions in the remaining
sequence, particularly amino acids 500 to 580, accounted for
most of the variation in the sequence patterns observed. Se-
quence patterns I to X were previously described by Ito et al.
(8), whereas patterns XI to XXIII were identified in this study.
Overall, sequence pattern XII was the most common (28 iso-
lates), followed by patterns X and XIII (11 isolates each).
Patterns III, VI, and VIII, previously described by Ito et al. (8),
were not identified in this sample.
Sequence pattern X (n  11) represented the previously
described mosaic PBP 2 sequence, confirming the presence of
this sequence in Australian gonococcal strains. Sequence pat-
tern XXIII was a variation of the previously described pattern
X mosaic sequence (26) (Fig. 1). Briefly, the first 430 amino
acids of this pattern XXIII mosaic sequence were nearly iden-
tical to those in the GenBank reference sequence (accession
number M32091) except for an additional Asp-345A codon,
whereas the remaining amino acids were similar to those of the
pattern X mosaic sequence but with the three substitutions
described by Takahata et al. (20).
Association of PBP 2 with antimicrobial susceptibility.
Overall, considerable variation in the ceftriaxone and penicillin
G MICs was observed for each of the PBP 2 sequence patterns
(Table 1). Significant associations with ceftriaxone susceptibil-
ity were observed for five PBP 2 patterns. Significantly higher
ceftriaxone MICs were observed for the N. gonorrhoeae strains
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FIG. 1. Partial PBP 2 amino acid sequences (positions 321 to 581) from the 109N. gonorrhoeae isolates used in this study. The sequences are classified
into different amino acid patterns (patterns I to XXIII) and are aligned with a GenBank N. gonorrhoeae sequence (accession number M32091). Sequence
patterns I to X were previously described by Ito et al. (8), whereas patterns XI to XXIII were identified in this study. The numbers of isolates with each
pattern are indicated in parentheses. Patterns III, VI, and VIII, previously described by Ito et al. (8), were not identified in this sample.
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with the mosaic PBP 2 pattern X (P  0.01), as well as those
with pattern XIII (P  0.001). Significantly lower ceftriaxone
MICs were observed for strains with patterns I (P  0.01), II
(P  0.01), and XII (P  0.05). Ten of the 11 strains with
mosaic pattern X were less susceptible to ceftriaxone (MICs 
0.06 g/ml), whereas one strain with pattern X and the one
strain with variant mosaic pattern XXIII were both sensitive
(MICs  0.03 g/ml and 0.008 g/ml, respectively; Table 1).
Significant associations with penicillin G susceptibility were
observed for five PBP 2 patterns (Table 2). Significantly higher
penicillin G MICs were observed for N. gonorrhoeae strains
with mosaic PBP 2 pattern X (P  0.001) as well as those with
pattern XX (P  0.01). Strains with patterns I, XV, and XXII
demonstrated significantly lower penicillin G MICs (P 0.01).
Only 4 of 95 N. gonorrhoeae strains with the additional Asp-
345A codon were susceptible to penicillin G, including strains
with PBP 2 patterns I (1 isolate), XII (1 isolate), and XXII (2
isolates). The two gonococcal strains with PBP 2 pattern XV,
which lacks the Asp-345A codon, were both susceptible to
penicillin G, with low MICs (MIC  0.0016 g/ml).
Association of N. gonorrhoeae typing with ceftriaxone sus-
ceptibility. There was considerable diversity among the isolates
tested, with seven auxotypes, 23 serotypes, and 64 NG MAST
sequence types observed. The PBP 2 amino acid patterns,
ceftriaxone MICs, auxotypes, serotypes, and sequence types for
the 50 N. gonorrhoeae isolates with reduced susceptibilities to
ceftriaxone are provided in Table 3. Briefly, the strains with
reduced susceptibilities to ceftriaxone did not have any partic-
ular type and were found to have a broad range of auxotypes,
serotypes, and genotypes.
Also of note was the presence of 14 isolates of sequence type
225, all with PBP 2 pattern XII. The ceftriaxone MICs for this
sequence type were 0.008 g/ml (n  6), 0.016 g/ml (n  4),
and 0.03 g/ml (n  4). There were another 14 isolates also of
PBP 2 pattern XII but of seven other sequence types (data not
shown) and with ceftriaxone MICs 0.008 g/ml (n  3), 0.016
g/ml (n  1), 0.03 g/ml (n  6), and 0.06 g/ml (n  4).
Sequence type 225 was the “clone” identified in the Danish clus-
ter (7), but no PBP 2 sequencing was performed in that study.
DISCUSSION
This study shows the considerable diversity that exists in PBP
2 proteins in N. gonorrhoeae strains less susceptible to ceftri-
axone. The 20 different amino acid sequences detected in-
cluded the 7 previously described by Ito et al. (8) and 13
additional variations. Many of the individual PBP 2 sequence
patterns displayed a range of ceftriaxone MICs and were found
in multiple gonococcal subtypes, although some were associ-
ated with significantly higher (patterns X and XIII) or lower
(patterns I, II, and XII) ceftriaxone MICs. As demonstrated in
a previous study (8), we also found a significant association
between the presence of the pattern X mosaic sequence and
reduced ceftriaxone susceptibility. However, in contrast to the
previous report (8), the mosaic sequences in our sample did
not account for a large proportion of strains with reduced
sensitivities to ceftriaxone, and only 6 of the 50 strains with
reduced sensitivities (MICs 0.06 g/ml or more) in this study
possessed the mosaic PBP 2 sequence (Table 3). Thus, the
presence of a mosaic PBP 2 sequence, previously assigned a
pivotal role in this phenomenon, could not account for the
majority of instances of this reduced sensitivity to ceftriaxone.
We raised further questions regarding the role of mosaic
sequences in conferring reduced ceftriaxone susceptibility
when we described a strain with variant mosaic pattern XXIII
that was fully susceptible to ceftriaxone (26). In this context,
the highly significant association between PBP 2 pattern XIII
TABLE 1. Ceftriaxone MICs for the various PBP 2 amino acid
patterns and associated N. gonorrhoeae NG MAST sequence types
PBP 2
pattern
No. of isolates with the following ceftriaxone
MIC (g/ml): No. of NG
MAST STsa
0.008 0.016 0.03 0.06 0.12 Total
I 6 6 6
II 5 5 3
IV 1 1 2 2
V 3 3 3 9 5
VII 2 1 3 3
IX 1 1 7 9 3
X 1 10 11 7
XI 2 2 2
XII 9 5 10 4 28 12
XIII 8 3 11 7
XIV 1 1 1
XV 2 2 2
XVI 1 1 1
XVII 2 1 3 2
XVIII 2 1 3 2
XIX 2 1 3 3
XX 1 2 3 1
XXI 3 3 2
XXII 2 1 3 3
XXIII 1 1 1
Total 36 9 14 43 7 109 64
a STs, sequence types.
TABLE 2. Penicillin G MICs for the various PBP 2 amino acid patterns
PBP 2
pattern
No. of isolates with the following penicillin G MIC (g/ml) or
characteristic:
0.06 0.125 0.25 0.5 1 2 PPNGa Total
I 1 3 1 1 6
II 1 3 1 5
IV 1 1 2
V 5 4 9
VII 1 2 3
IX 1 7 1 9
X 2 9 11
XI 1 1 2
XII 1 2 19 5 27
XIII 9 1 1 11
XIV 1 1
XV 2 2
XVI 1 1
XVII 2 1 3
XVIII 3 3
XIX 1 2 3
XX 3 3
XXI 1 1 1 3
XXII 2 1 3
XXIII 1 1
Total 6 4 8 5 47 28 10
a PPNG, penicillinase-producing N. gonorrhoeae.
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and reduced susceptibility to ceftriaxone was also of particular
interest. This PBP 2 pattern contained a substitution at posi-
tion 501 (A501V), and all 11 strains with pattern XIII were less
susceptible to ceftriaxone, with MICs of 0.06 g/ml or greater.
In fact, 22 of the 25 strains in our sample containing a substi-
tution at position 501 (A501V or A501T; patterns VII, XI,
XIII, XVII, XVIII, and XXI) were less susceptible to ceftri-
axone and comprised 6 of the 7 strains with MICs of 0.125
g/ml. During transformation experiments with mosaic penA
sequences, Takahata et al. (20) found that a spontaneous mu-
tant with a single A501V mutation was selected with cepha-
lexin. Subsequent analysis revealed that this A501V mutation
led to two- to fourfold increases in the MICs of cefixime and
other cephems (20). Ito et al. (8) also observed that all five
strains with PBP 2 pattern VII were less susceptible to ceftri-
axone (8). These changes at position 501 were also present in
some gonococci less susceptible to ceftriaxone in the studies of
Ito et al. (8) and Lindberg et al. (12) but were not specifically
remarked upon by either group. Overall, this suggests that the
mutations at position 501 are also of interest and, based on our
data, are more significant as a contribution to ceftriaxone sus-
ceptibility than the mosaic sequences. However, questions are
again raised over the relevance of this mutation in isolation,
given that all three strains in our study with pattern XXI
(which contains the A501V mutation) were fully susceptible to
ceftriaxone (MICs  0.008 g/ml).
It was also shown in this study that while particular N.
gonorrhoeae genotypes, e.g., sequence type 5, were associated
with decreased susceptibility to ceftriaxone, in general, this
reduced susceptibility to ceftriaxone was not restricted to any
particular genotype and was observed in strains of a broad
range of auxotypes, serotypes, and genotypes. Thus, the mech-
anisms responsible for the reduced susceptibility to ceftriaxone
appear to be present in a broad range of gonococcal types and
strains and were not associated with a particular subtype, as
has been observed previously (7, 8). Both of those earlier
studies were with gonococci isolated in a limited geographic
area over a defined period, whereas this study was of gonococci
selected for their temporal and geographic diversities. Other
broadly based studies of the diagnostic features (11, 14) and
the pathogenic features (17) of gonococci have also revealed a
wider distribution of gonococcal subtypes with a particular
characteristic than that revealed by earlier and more narrowly
based studies. The findings of those earlier studies and those of
this study are thus consistent with the known population dy-
namics of gonococci (9, 23), and the earlier data probably
reflect the expansion of a particular subtype within a wider
gonococcal population at a particular time and place. The
presence in both Denmark and Australia of N. gonorrhoeae NG
MAST sequence type 225 strains with some increase in the
ceftriaxone MIC (MIC  0.03 g/ml) also suggests the possi-
bility of the international spread of these strains. The Interna-
tional spread of gonococci with other specific characteristics
has also been documented recently (25).
The clinical significance of these findings is difficult to de-
termine at present. The history of antimicrobial resistance in
N. gonorrhoeae indicates that problems with any antibiotic that
is used extensively for the treatment of N. gonorrhoeae disease
will eventually be encountered (5, 22). The emergence of N.
gonorrhoeae strains with reduced susceptibilities to ceftriaxone
and other expanded-spectrum cephalosporins suggests that the
gonococci are now developing mechanisms of resistance to yet
another important group of antibiotics. These isolates with
reduced susceptibilities to ceftriaxone are often also quinolone
resistant (7), and this was also the case with the isolates studied
here (data not shown). Although treatment failure with oral
expanded-spectrum agents, including cefixime, which is not
available in Australia, have been recorded in Japan (16), it
should be noted that no documented treatment failures have
been associated with the injectable agent ceftriaxone when the
higher 250-mg dose recommended for use in Australia is used,
even for strains containing the mosaic penA sequence (22).
Thus, it would appear that additional resistance mechanisms
are required before we will see gonococci that are fully resis-
tant to ceftriaxone.
Overall, the results of our study show that mosaic PBP 2
sequences alone cannot account for the reduced ceftriaxone
sensitivity observed in our N. gonorrhoeae strains and that
strains exhibiting this phenotype are not necessarily of a par-
ticular subtype. Furthermore, the results suggest that gradual
mutation in the N. gonorrhoeae penA gene sequence, in addi-
tion to genetic recombination, which occurs frequently in
TABLE 3. Profiles for the 50 N. gonorrhoeae isolates with reduced
susceptibilities to ceftriaxone (MIC  0.06 g/ml), indicating the
PBP 2 amino acid pattern, ceftriaxone MIC, auxotype,
serotype, and genotype dataa
PBP 2
pattern
Ceftriaxone MIC
(g/ml)
NG MAST
ST Auxotype Serotype
b No. of
isolates
IV 0.06 69 NR Brpyut 1
IV 0.12 327 Pro Brpust 1
V 0.06 1,410 Pro Bropyst 2
V 0.06 1,688 Pro Bropyst 1
VII 0.06 1,619 Pro Brpyust 1
VII 0.06 1,622 Pro Byust 1
VII 0.12 1,422 Pro Brpyust 1
IX 0.06 5 NR Bropyst 6
IX 0.06 21 NR Bopyst 1
X 0.06 1,414 Pro Bpyust 3
X 0.06 1,424 Pro Bpyust 3
X 0.06 1,677 Pro Byust 1
X 0.06 326 Pro Bropyst 1
X 0.06 835 Pro Bpyust 1
X 0.06 925 Pro Boys 1
XI 0.06 1,420 Pro Bro 1
XI 0.06 5 NR Bropyst 1
XII 0.06 1,426 NR Brpyst 1
XII 0.06 1,703 NR Bopt 1
XII 0.06 604 NR Bropyst 1
XII 0.06 604 NR Broypt 1
XIII 0.06 1,409 NR Bropyst 2
XIII 0.06 1,623 NR Bropyst 4
XIII 0.06 1,624 NR Byvut 1
XIII 0.06 1,676 NR Byvut 1
XIII 0.12 1,148 Pro Bropyst 1
XIII 0.12 1,413 NR Bropyst 1
XIII 0.12 1,425 NR Bropyst 1
XVII 0.06 1,342 Pro Bropyst 2
XVII 0.12 1,620 Pro Bropyst 1
XVIII 0.06 864 Pro Bopt 2
XVIII 0.12 1,621 Pro Bropyst 1
XX 0.06 211 NR Arst 2
a Nine profiles were identified for more than one isolate. ST, sequence type;
NR, nonrequiring; Pro, proline requiring.
b Serotype by use of the nomenclature of Bygdeman (4).
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gonococci (23), contributes not only to reduced susceptibility
to ceftriaxone but also to the diversity of changes observed
here. The separate phenomenon of strain diversity seen also,
but separately, reflects the high rate of transformation that
occurs in N. gonorrhoeae. Other mechanisms that may confer
reduced susceptibility to newer cephalosporins, including mu-
tations in the ponA (PBP 1) gene, have been proposed (21).
Thus, further investigation is needed to fully understand the
impacts of these genetic mechanisms both alone and in com-
bination. We emphasize that N. gonorrhoeae strains with re-
duced susceptibilities to ceftriaxone represent a potential
threat to current treatment regimens. Hence, the continued
spread of these strains needs to be closely monitored.
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